Den blindede periode blev efterfulgt af en åben periode, hvor patienterne modtog Humira 40 mg hver anden uge subkutant i op til yderligere 28 uger.
The blinded period was followed by an open − label period during which patients received Humira 40 mg every other week subcutaneously for up to an additional 28 weeks.